By Nicole Ireland

Health Canada has approved the first drug designed to treat postpartum depression.

Recommended Videos

Zuranolone, sold under the brand name Zurzuvae, is a pill taken once a day for 14 days and can start relieving depressive symptoms in as few as three days.

Manufactured by Biogen, the drug has been approved for use in the United States since late 2023 and is also authorized in the U.K. and the European Union.

According to Health Canada’s website, one in five women experience a depression or anxiety disorder during or after pregnancy.

Zuranolone is a welcome drug for women suffering from moderate to severe postpartum depression, said Dr. Crystal Clark, Canada Research Chair in reproductive mental health and a psychiatrist at Women’s College Hospital in Toronto.

Sele

See Full Page